150 related articles for article (PubMed ID: 8416794)
1. Mechanisms through which gangliosides inhibit PDGF-stimulated mitogenesis in intact Swiss 3T3 cells: receptor tyrosine phosphorylation, intracellular calcium, and receptor binding.
Yates AJ; VanBrocklyn J; Saqr HE; Guan Z; Stokes BT; O'Dorisio MS
Exp Cell Res; 1993 Jan; 204(1):38-45. PubMed ID: 8416794
[TBL] [Abstract][Full Text] [Related]
2. Gangliosides inhibit platelet-derived growth factor-stimulated growth, receptor phosphorylation, and dimerization in neuroblastoma SH-SY5Y cells.
Hynds DL; Summers M; Van Brocklyn J; O'Dorisio MS; Yates AJ
J Neurochem; 1995 Nov; 65(5):2251-8. PubMed ID: 7595514
[TBL] [Abstract][Full Text] [Related]
3. Gangliosides inhibit platelet-derived growth factor-stimulated receptor dimerization in human glioma U-1242MG and Swiss 3T3 cells.
Van Brocklyn J; Bremer EG; Yates AJ
J Neurochem; 1993 Jul; 61(1):371-4. PubMed ID: 8515285
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells.
Pukac LA; Carter JE; Ottlinger ME; Karnovsky MJ
J Cell Physiol; 1997 Jul; 172(1):69-78. PubMed ID: 9207927
[TBL] [Abstract][Full Text] [Related]
5. Gangliosides GM1, GM2 and GM3 inhibit the platelet-derived growth factor-induced signalling transduction pathway in vascular smooth muscle cells by different mechanisms.
Sachinidis A; Kraus R; Seul C; Meyer zu Brickwedde MK; Schulte K; Ko Y; Hoppe J; Vetter H
Eur J Cell Biol; 1996 Sep; 71(1):79-88. PubMed ID: 8884181
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
[TBL] [Abstract][Full Text] [Related]
7. Ganglioside-mediated modulation of cell growth, growth factor binding, and receptor phosphorylation.
Bremer EG; Hakomori S; Bowen-Pope DF; Raines E; Ross R
J Biol Chem; 1984 Jun; 259(11):6818-25. PubMed ID: 6327695
[TBL] [Abstract][Full Text] [Related]
8. Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity.
Huang JS; Nishimura J; Huang SS; Deuel TF
J Cell Biochem; 1984; 26(4):205-20. PubMed ID: 6099364
[TBL] [Abstract][Full Text] [Related]
9. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
Kovalenko M; Gazit A; Böhmer A; Rorsman C; Rönnstrand L; Heldin CH; Waltenberger J; Böhmer FD; Levitzki A
Cancer Res; 1994 Dec; 54(23):6106-14. PubMed ID: 7954456
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
Major TC; Keiser JA
J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
[TBL] [Abstract][Full Text] [Related]
11. Gangliosides have a bimodal effect on DNA synthesis in U-1242 MG human glioma cells.
Saqr HE; Lee MC; Burkman AM; Yates AJ
J Neurosci Res; 1995 Jul; 41(4):491-500. PubMed ID: 7473880
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
[TBL] [Abstract][Full Text] [Related]
13. Calcium and growth responses of hyperresponsive airway smooth muscle to different isoforms of platelet-derived growth factor (PDGF).
Zacour ME; Tolloczko B; Martin JG
Can J Physiol Pharmacol; 2000 Nov; 78(11):867-73. PubMed ID: 11100934
[TBL] [Abstract][Full Text] [Related]
14. Modulation of platelet-derived growth factor receptor function in BP3T3, a chemically transformed BALB/c-3T3 cell line.
Grundy P; Bishayee S; Disa S; Scher CD
Cancer Res; 1989 Jul; 49(13):3581-6. PubMed ID: 2543499
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human neuroblastoma cell proliferation and EGF receptor phosphorylation by gangliosides GM1, GM3, GD1A and GT1B.
Mirkin BL; Clark SH; Zhang C
Cell Prolif; 2002 Apr; 35(2):105-15. PubMed ID: 11952645
[TBL] [Abstract][Full Text] [Related]
16. The role of gangliosides in the interaction of a growth inhibitor with mouse LM cells.
Bascom CC; Sharifi BG; Melkerson LJ; Rintoul DA; Johnson TC
J Cell Physiol; 1985 Dec; 125(3):427-35. PubMed ID: 4066767
[TBL] [Abstract][Full Text] [Related]
17. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
[TBL] [Abstract][Full Text] [Related]
18. STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation.
Sachsenmaier C; Sadowski HB; Cooper JA
Oncogene; 1999 Jun; 18(24):3583-92. PubMed ID: 10380880
[TBL] [Abstract][Full Text] [Related]
19. Use of selective tyrosine kinase blockers to monitor growth factor receptor dephosphorylation in intact cells.
Böhmer FD; Böhmer A; Obermeier A; Ullrich A
Anal Biochem; 1995 Jul; 228(2):267-73. PubMed ID: 8572305
[TBL] [Abstract][Full Text] [Related]
20. Ganglioside modulation of the PDGF receptor. A model for ganglioside functions.
Yates AJ; Saqr HE; Van Brocklyn J
J Neurooncol; 1995; 24(1):65-73. PubMed ID: 8523078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
